Akero Therapeutics (AKRO) released preliminary topline week 96 results from SYMMETRY, a Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin, or EFX ...

Results of another phase 2b study – called SYMMETRY – showed that efruxifermin was unable to hit its main objective as a treatment for patients with compensated cirrhosis (F4) due to NASH ...

a Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin (EFX) in patients with biopsy-confirmed compensated cirrhosis (F4), Child-Pugh Class A, due to ...

Though things are looking up for Akero, the stock still looks risky. Akero Therapeutics is developing efruxifermin as a potential treatment for metabolic dysfunction-associated steatohepatitis ...

The company has announced a forthcoming investor call to discuss the 96-week data update from its SYMMETRY trial, which evaluates the efficacy of efruxifermin (EFX) in patients with compensated ...

Over the 15 months in between, more study participants responded to Akero’s drug, called efruxifermin. Overall, 29% of people given the highest tested dose of efruxifermin experienced ...

In October 2024, Akero Therapeutics reported a 36-week analysis of the SYMMETRY study of efruxifermin. Efruxifermin was not statistically significant in topping the placebo in improving liver ...

A 50-milligram dose of efruxifermin resulted in the reversal of cirrhosis in 39% of the patients while none of them experienced any further worsening of MASH, as per the company’s press release.

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious ...

Akero Therapeutics is developing efruxifermin as a potential treatment for metabolic dysfunction-associated steatohepatitis (MASH), a non-alcohol-related liver disease. MASH is linked to a ...